Research from the University of Pittsburgh indicates potential relief for sleep apnea sufferers through a newly tested drug called AD109. Results from a large phase 3 clinical trial, published in the American Journal of Respiratory and Critical Care Medicine, suggest that AD109 can significantly reduce breathing interruptions during sleep without reliance on continuous positive airway pressure (CPAP) machines.
Read More
Sleep apnea, particularly Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS), impacts approximately 4% of the population in France, with many cases going undiagnosed, especially among women. The condition occurs when the pharynx repeatedly collapses during sleep, leading to pauses in breathing that cause disturbances like snoring, fatigue, daytime sleepiness, and irritability. More critically, it elevates the risk for serious health issues such as heart disease, high blood pressure, type 2 diabetes, and obesity. The prevalence of sleep apnea increases with age, affecting about 30.5% of individuals over 65, according to Inserm, the French National Institute of Health and Medical Research.
While CPAP machines are the standard treatment, they are not suitable for everyone. Other options exist, such as mandibular advancement devices, subcutaneous implants, and surgery, but they have limitations that often leave many without treatment.
The clinical trial for AD109 involved 646 participants, averaging 58 years old, from 69 hospitals in the US and Canada. The double-blind study lasted six months and found that participants who received AD109 experienced a 44% reduction in breathing interruptions. Improved oxygen levels and a decrease in the severity of sleep apnea were also observed. Notably, over 40% of those treated saw enough improvement to reduce their severity classification, while 18% achieved complete control. In contrast, those on a placebo experienced only an 18% reduction in interruptions.
Dr. Patrick John Strollo, a sleep medicine specialist and lead author of the study, stated that the findings provide encouraging evidence that targeting neuromuscular issues can yield significant clinical outcomes. He noted that AD109 could serve as an effective alternative for patients who struggle with or prefer not to use CPAP devices. With continued advancements like this, patients may soon experience quieter nights free from devices.